$CDXS
CODEXIS, INC.

2013 Q4 Form 10-Q Financial Statement

#000120037513000011 Filed on November 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $9.525M $3.943M $7.912M
YoY Change 20.39% -85.03% -76.38%
Cost Of Revenue $4.764M $494.0K $5.779M
YoY Change -17.56% -92.28% -55.77%
Gross Profit $4.761M $3.449M $2.133M
YoY Change 123.21% -82.71% -89.56%
Gross Profit Margin 49.98% 87.47% 26.96%
Selling, General & Admin $5.783M $5.832M $7.286M
YoY Change -20.63% -26.26% -25.52%
% of Gross Profit 121.47% 169.09% 341.58%
Research & Development $8.829M $6.831M $10.59M
YoY Change -16.66% -51.86% -31.86%
% of Gross Profit 185.44% 198.06% 496.67%
Depreciation & Amortization $2.470M $2.610M $2.930M
YoY Change -15.7% -16.88% -2.66%
% of Gross Profit 51.88% 75.67% 137.37%
Operating Expenses $19.38M $13.16M $23.66M
YoY Change -18.1% -53.83% -38.38%
Operating Profit -$14.62M -$9.214M -$21.53M
YoY Change -32.11% 327.37% 19.79%
Interest Expense $10.00K $10.00K $40.00K
YoY Change -75.0% -83.33% -50.0%
% of Operating Profit
Other Income/Expense, Net -$20.00K $22.00K -$10.00K
YoY Change 100.0% -51.11% -96.67%
Pretax Income -$9.858M -$9.227M -$15.71M
YoY Change -37.25% 331.17% 206.68%
Income Tax -$50.00K $35.00K -$170.0K
% Of Pretax Income
Net Earnings -$9.813M -$9.262M -$15.54M
YoY Change -36.85% 301.13% 193.34%
Net Earnings / Revenue -103.02% -234.9% -196.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$252.1K -$243.0K -$413.3K
COMMON SHARES
Basic Shares Outstanding 38.11M shares 38.09M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.14M $29.92M $45.53M
YoY Change -44.79% -40.63% -14.87%
Cash & Equivalents $22.13M $26.91M $32.00M
Short-Term Investments $3.005M $3.009M $13.52M
Other Short-Term Assets $3.800M $1.900M $5.400M
YoY Change -29.63% -63.46% 134.78%
Inventory $1.487M $2.101M $1.302M
Prepaid Expenses
Receivables $5.413M $2.688M $7.545M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.78M $36.64M $59.77M
YoY Change -40.13% -51.01% -24.56%
LONG-TERM ASSETS
Property, Plant & Equipment $8.446M $13.81M $16.65M
YoY Change -49.27% -30.61% -31.13%
Goodwill $3.241M $3.241M $3.241M
YoY Change 0.0% 0.0%
Intangibles $9.560M $10.40M $12.93M
YoY Change -26.09%
Long-Term Investments $800.0K $1.100M $3.600M
YoY Change -77.78% -69.44% -65.05%
Other Assets $306.0K $361.0K $2.237M
YoY Change -86.32% -90.24% 130.14%
Total Long-Term Assets $23.06M $29.79M $40.20M
YoY Change -42.63% -32.6% -29.1%
TOTAL ASSETS
Total Short-Term Assets $35.78M $36.64M $59.77M
Total Long-Term Assets $23.06M $29.79M $40.20M
Total Assets $58.84M $66.44M $99.97M
YoY Change -41.14% -44.17% -26.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.961M $1.490M $3.654M
YoY Change 8.4% -76.35% -64.74%
Accrued Expenses $1.612M $2.140M $6.948M
YoY Change -76.8% -82.31% -5.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.20M $9.218M $16.28M
YoY Change -31.22% -55.47% -42.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.044M $5.183M $3.943M
YoY Change 27.92% -2.21% 14.12%
Total Long-Term Liabilities $5.044M $5.183M $3.943M
YoY Change 27.92% -2.21% 14.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.20M $9.218M $16.28M
Total Long-Term Liabilities $5.044M $5.183M $3.943M
Total Liabilities $17.36M $14.40M $20.23M
YoY Change -14.18% -44.61% -36.29%
SHAREHOLDERS EQUITY
Retained Earnings -$256.9M -$247.0M -$215.6M
YoY Change 19.16% 16.71%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.48M $50.87M $78.44M
YoY Change
Total Liabilities & Shareholders Equity $58.84M $66.44M $99.97M
YoY Change -41.14% -44.17% -26.45%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$9.813M -$9.262M -$15.54M
YoY Change -36.85% 301.13% 193.34%
Depreciation, Depletion And Amortization $2.470M $2.610M $2.930M
YoY Change -15.7% -16.88% -2.66%
Cash From Operating Activities -$3.910M -$8.530M -$4.730M
YoY Change -17.34% 120.41% 63.1%
INVESTING ACTIVITIES
Capital Expenditures -$730.0K $190.0K -$300.0K
YoY Change 143.33% -337.5% -89.76%
Acquisitions
YoY Change
Other Investing Activities $290.0K $2.850M $11.10M
YoY Change -97.39% -76.68% 710.22%
Cash From Investing Activities -$440.0K $3.040M $10.80M
YoY Change -104.07% -74.96% -792.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -440.0K 10.00K 370.0K
YoY Change -218.92% -98.33% 270.0%
NET CHANGE
Cash From Operating Activities -3.910M -8.530M -4.730M
Cash From Investing Activities -440.0K 3.040M 10.80M
Cash From Financing Activities -440.0K 10.00K 370.0K
Net Change In Cash -4.790M -5.480M 6.440M
YoY Change -174.38% -161.78% -247.71%
FREE CASH FLOW
Cash From Operating Activities -$3.910M -$8.530M -$4.730M
Capital Expenditures -$730.0K $190.0K -$300.0K
Free Cash Flow -$3.180M -$8.720M -$4.430M
YoY Change -28.22% 130.08% -14866.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2156000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3654000 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1490000 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2688000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7545000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-508000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
63000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6948000 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2140000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34172000 USD
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37780000 USD
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
139000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-136000 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
297776000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
294128000 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
478000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
150000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2665000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2531000 USD
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8327000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6545000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8327000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6545000 shares
CY2013Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
100000 USD
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
0 USD
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
22000 USD
CY2012Q4 us-gaap Assets
Assets
99965000 USD
CY2013Q3 us-gaap Assets
Assets
66436000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
59769000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
36644000 USD
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
24646000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41873000 USD
CY2013Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
25155000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
41936000 USD
CY2013Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
0 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
0 USD
CY2013Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
509000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
63000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26911000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25762000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25573000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-189000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5092000 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2013Q3 us-gaap Cash
Cash
5800000 USD
CY2012Q4 us-gaap Cash
Cash
7200000 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable and restricted cash. Cash and cash equivalents, marketable securities and restricted cash are invested through banks and other financial institutions in the United States, as well as in other foreign countries. Such deposits may be in excess of insured limits.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk with respect to accounts receivable exists to the extent of amounts presented in the condensed consolidated financial statements. The Company estimates an allowance for doubtful accounts through specific identification of potentially uncollectible accounts receivable based on an analysis of its accounts receivable aging. Uncollectible accounts receivable are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from its estimates and could be material to its consolidated financial position, results of operations, and cash flows.</font></div></div>
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6397000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
24868000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9790000 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
494000 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2248000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2186000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1299000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
166000 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3340000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3495000 USD
CY2013Q3 us-gaap Goodwill
Goodwill
3241000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1161000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6822000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5307000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-93000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-62000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2140000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9227000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-833000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14875000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31530000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
443000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-41000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
169000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4077000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2164000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2390000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1642000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1923000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-155000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2077000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1727000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
614000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1080000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
581000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
37000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1321000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2824000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-600000 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12934000 USD
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10403000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
662000 USD
CY2013Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1064000 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
2101000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
1302000 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
802000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
588000 USD
CY2013Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
235000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
52000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
210000 USD
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
61000 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
53000 USD
cdxs Marketable Securities Included In Non Current Asset
MarketableSecuritiesIncludedInNonCurrentAsset
P1Y
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99965000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66436000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9218000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16283000 USD
CY2013Q3 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
600000 USD
CY2013Q3 us-gaap Marketable Securities
MarketableSecurities
3009000 USD
CY2012Q4 us-gaap Marketable Securities
MarketableSecurities
13524000 USD
CY2013Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1067000 USD
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3623000 USD
CY2013Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21100000 USD
CY2012Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
24800000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Codexis, Inc. (the "Company") was incorporated in the state of Delaware in January 2002. The Company engineers enzymes for the pharmaceutical and complex chemistry industries. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. There are currently over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> pharmaceutical firms using its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assists customers in discovering or enhancing enzymes variants by applying its CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once the Company identifies potentially beneficial mutations, it tests combinations of these mutations until it has created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows the Company to make continuous, efficient improvements to the performance of its enzymes. </font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these Notes to Condensed Consolidated Financial Statements, the &#8220;Company&#8221; refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
894000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5906000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13713000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19093000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7155000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-9262000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15318000 USD
us-gaap Net Income Loss
NetIncomeLoss
-31489000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2309000 USD
CY2012Q4 us-gaap Noncurrent Assets
NoncurrentAssets
31821000 USD
CY2013Q3 us-gaap Noncurrent Assets
NoncurrentAssets
24573000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reporting_unit
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
28497000 USD
us-gaap Operating Expenses
OperatingExpenses
53692000 USD
us-gaap Operating Expenses
OperatingExpenses
95151000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
13157000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9214000 USD
cdxs Maturity Date Of Highly Liquid Investments
MaturityDateOfHighlyLiquidInvestments
P3M
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
288000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14765000 USD
cdxs Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
1912000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
894000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20800000 USD
cdxs Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
0 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
32000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
253000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
275000 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
724000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13410000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
150000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-31295000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
18211000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
719000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2677000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3047000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3031000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2947000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5790000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
361000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2237000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
58000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
17000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
58000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
172000 USD
CY2012Q3 us-gaap Other Expenses
OtherExpenses
45000 USD
us-gaap Other Expenses
OtherExpenses
320000 USD
us-gaap Other Expenses
OtherExpenses
288000 USD
CY2013Q3 us-gaap Other Expenses
OtherExpenses
22000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3943000 USD
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5183000 USD
CY2012Q3 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
800000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20638000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
447000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2632000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5395000 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1935000 USD
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51341000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50794000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13809000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16650000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
328000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
49049000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
7236000 USD
CY2012Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
18569000 USD
CY2013Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
2867000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6831000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22776000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46190000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14191000 USD
CY2013Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
911000 USD
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1511000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215556000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-247045000 USD
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
632000 USD
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
2247000 USD
us-gaap Revenues
Revenues
80386000 USD
CY2012Q3 us-gaap Revenues
Revenues
26341000 USD
us-gaap Revenues
Revenues
22397000 USD
CY2013Q3 us-gaap Revenues
Revenues
3943000 USD
CY2013Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
1076000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
15161000 USD
CY2012Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
7140000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
29090000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21126000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24093000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5832000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7909000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3361000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4543000 USD
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
626000 USD
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1466000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
78440000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
50874000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
275000 USD
CY2012Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
724000 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
32000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
88000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's management regularly assesses these estimates which primarily affect revenue recognition, the valuation of marketable securities and accounts receivable, intangible assets, goodwill arising out of business acquisitions, inventories, accrued liabilities, common stock, and stock options and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38102000 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37116000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38002000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36494000 shares
cdxs Comprehensive Loss
ComprehensiveLoss
-31214000 USD
cdxs Comprehensive Loss
ComprehensiveLoss
-15065000 USD
CY2013Q3 cdxs Comprehensive Loss
ComprehensiveLoss
-9230000 USD
CY2012Q3 cdxs Comprehensive Loss
ComprehensiveLoss
-1585000 USD
CY2012Q3 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
165000 USD
CY2013Q3 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
753000 USD
CY2013Q3 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 security
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2012Q4 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 security
cdxs Number Revenue Recognition Criteria
NumberRevenueRecognitionCriteria
4 Criteria
cdxs Numberof Customers
NumberofCustomers
50 pharmaceutical_firm
cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 USD
cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
8376000 USD
CY2012Q4 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
16622000 USD
CY2013Q3 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
13561000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001200375
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38105532 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
CODEXIS INC

Files In Submission

Name View Source Status
R40.htm Edgar Link pending
0001200375-13-000011-index-headers.html Edgar Link pending
0001200375-13-000011-index.html Edgar Link pending
0001200375-13-000011.txt Edgar Link pending
0001200375-13-000011-xbrl.zip Edgar Link pending
cdxs-20130930.xml Edgar Link completed
cdxs-20130930.xsd Edgar Link pending
cdxs-20130930_cal.xml Edgar Link unprocessable
cdxs-20130930_def.xml Edgar Link unprocessable
cdxs-20130930_lab.xml Edgar Link unprocessable
cdxs-20130930_pre.xml Edgar Link unprocessable
cdxs_20130930x10q.htm Edgar Link pending
cdxs_20130930xex311.htm Edgar Link pending
cdxs_20130930xex312.htm Edgar Link pending
cdxs_20130930xex321.htm Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit102.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending